Clinical Trial Update: A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C [Phase 2]

View source ↗

Summary

A Phase 2a dose-ranging study assessing VX-135 with ribavirin in treatment-naïve chronic hepatitis C patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ribavirin (ribavirin)
• VX-135

Snippet

Sponsor: Alios Biopharma Inc. | Conditions: Chronic Hepatitis C | Phase 2 | Status: COMPLETED